Skin mites enhance virtual memory T cell responses against immune checkpoint inhibitor-resistant tumors 2304047

J Jihoon Oh (School of Chemical and Biological Engineering and Institute of Chemical Processes, Seoul National University) T Tomoaki Yoshida (National Institutes of Health) M Maria Calvijo-Salomon (National Institutes of Health) J Jonathan Badger (National Institutes of Health) G Giorgio Trinchieri (National Cancer Institute) B Barbara Rehermann (NIDDK, National Institutes of Health)

Abstract

Abstract Introduction Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, yet some patients remain non-responsive. The current study aims to investigate the role of complex microbiota and commensals across body sites in this response. Methods Because traditional laboratory mouse models are limited by their lack of complex, natural microbiota, we explored ICI therapy in a colony of ‘wildling’ mice, the founders of which were generated by re-deriving C57BL/6 embryos in wild mice. Results Wildling mice significantly enhanced CD8 T cell—dependent antitumor responses upon ICI, in comparison to conventional laboratory mice on the same genetic background. This enhanced anti-tumor activity required IFN-γ and CXCR3—CXCL9/10—mediated recruitment of CXCR3+ CD49d⁻ virtual memory (TVM) CD8+ T cells. Wildling mice had markedly expanded, highly functional TVM cells across lymphoid and non-lymphoid tissues, with heightened effector signatures, increased cytokine responsiveness, and superior intratumoral accumulation upon ICI treatment. Screening of natural microbiota and commensals revealed that skin mites induced the wildling phenotype. Transfer of skin mites to conventional laboratory mice induced a substantial expansion of CD49d⁻ TVM cells and ICI responsiveness, whereas depletion of mites from wildling mice reduced both TVM abundance and ICI efficacy. Analysis of public databases demonstrated increased abundance of CD8 T cells with a TVM transcriptional signature correlated with melanoma of ICI responders, supporting the translational relevance of these findings. Conclusion This study identifies skin mite—driven expansion of CD49d⁻ TVM cells in anti-tumor immunity and ICI responsiveness. These findings offer new insights into targeting skin mites and Tvm as a strategy to overcome resistance to ICIs in cancer treatment. Funding Source Intramural research programs of NIDDK, NIH Topic Categories Tumor Immunology: Checkpoints, Prevention, and Treatment (TIPT)

Article Details

Volume / Issue Vol. 215, Issue Supplement_1
Published August 01, 2026
ISSN 0022-1767
Publisher American Association of Immunologists

Authors (6)

J

Jihoon Oh

School of Chemical and Biological Engineering and Institute of Chemical Processes, Seoul National University

T

Tomoaki Yoshida

National Institutes of Health

M

Maria Calvijo-Salomon

National Institutes of Health

J

Jonathan Badger

National Institutes of Health

G

Giorgio Trinchieri

National Cancer Institute

B

Barbara Rehermann

NIDDK, National Institutes of Health